| 1 | Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 Fusion. 2021;10:582 doi: 10.3390/jcm10040582 |
| 2 | Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer. 2021;13:4808 doi: 10.3390/cancers13194808 |
| 3 | Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors. 2021;18:1455 doi: 10.1021/acs.molpharmaceut.1c00018 |
| 4 | Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. 2020;22: doi: 10.1186/s13058-020-01325-3 |
| 5 | The role of interactomic interactions in tamoxifen-resistant breast cancer: new approaches to searching for the mechanisms of pathogenesis. 2020;9:80 doi: 10.17116/onkolog2020906180 |
| 6 | An Interdependence between Estrogen Receptor 1 Gene Polymorphisms and Susceptibility to Breast Cancer. 2021;1: doi: 10.5812/tms.117221 |
| 7 | Widespread Exaptation of L1 Transposons for Transcription Factor Binding in Breast Cancer. 2021;22:5625 doi: 10.3390/ijms22115625 |
| 8 | Understanding the interaction of estrogenic ligands with estrogen receptors: a survey of the functional and binding kinetic studies. 2020;38:142 doi: 10.1080/26896583.2020.1761204 |
| 9 | Opportunities for Antigen Discovery in Metastatic Breast Cancer. 2020;11: doi: 10.3389/fimmu.2020.570049 |
| 10 | Identification and targeting of selective vulnerability rendered by tamoxifen resistance. 2020;22: doi: 10.1186/s13058-020-01315-5 |
| 11 | Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer. 2021;190:189 doi: 10.1007/s10549-021-06383-5 |
| 12 | microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer. 2020;10: doi: 10.3389/fonc.2020.00753 |
| 13 | Integrated transcription factor profiling with transcriptome analysis identifies L1PA2 transposons as global regulatory modulators in a breast cancer model. 2021;11: doi: 10.1038/s41598-021-86395-9 |
| 14 | Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis. 2021;10:2966 doi: 10.3390/cells10112966 |
| 15 | PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α–Positive Breast Cancer Cells. 2021;19:1688 doi: 10.1158/1541-7786.MCR-21-0103 |
| 16 | Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer. 2020;21:8807 doi: 10.3390/ijms21228807 |
| 17 | Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer. 2020;21:4068 doi: 10.3390/ijms21114068 |
| 18 | Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis. 2021;11: doi: 10.3389/fonc.2021.645698 |
| 19 | Genomic Assays in Node Positive Breast Cancer Patients: A Review. 2021;10: doi: 10.3389/fonc.2020.609100 |
| 20 | Exomes of Ductal Luminal Breast Cancer Patients from Southwest Colombia: Gene Mutational Profile and Related Expression Alterations. 2020;10:698 doi: 10.3390/biom10050698 |
| 21 | Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis. 2020;7: doi: 10.3389/fmolb.2020.00134 |
| 22 | Identification of Key lncRNA–mRNA Pairs and Functional lncRNAs in Breast Cancer by Integrative Analysis of TCGA Data. 2021;12: doi: 10.3389/fgene.2021.709514 |
| 23 | Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects. 2020;10: doi: 10.3389/fonc.2020.587671 |
| 24 | Identification of molecular biomarkers and pathways of NSCLC: insights from a systems biomedicine perspective. 2021;19: doi: 10.1186/s43141-021-00134-1 |
| 25 | FOXO transcription factor family in cancer and metastasis. 2020;39:681 doi: 10.1007/s10555-020-09883-w |
| 26 | Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis. 2021;12: doi: 10.1007/s12672-021-00432-7 |
Journal of Cancer Metastasis and Treatment
